timothy sykes logo
CELC Stock Surges As VIKTORIA-1 Trial Hits Phase 3 Milestone Thumbnail
G Google News

CELC Stock Surges As VIKTORIA-1 Trial Hits Phase 3 Milestone

JACK KELLOGG•UPDATED MAY. 4, 2026, 11:32 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Celcuity Inc. stocks have been trading up by 15.33 percent following highly positive news on its oncology pipeline progress.

Candlestick Chart

Live Update At 11:32:00 EDT: On Monday, May 04, 2026 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 15.33%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CELC has turned into a momentum biotech name, and the tape shows it. Over the last dozen trading days, Celcuity Inc. has run from closes near $117–$120 up to $144.91 most recently. That’s a strong, steady uptrend with higher lows and mostly higher highs, not a one‑day fluke.

On 2026/05/04, CELC opened around $142.12, dipped hard to $136.06 at the open flush, then reclaimed and closed near the high of the day. That intraday reversal tells traders buyers are eager to step in on weakness. The 5‑minute chart around the $145 area shows tight trading, with CELC cycling between roughly $144.5 and $149.6. That kind of consolidation after a run usually signals active price discovery, not exhausted momentum.

Fundamentally, Celcuity Inc. is still a classic development‑stage biotech. The latest quarter shows about -$50.97M in net loss and negative free cash flow near -$36.45M. Returns on equity and assets are deeply negative, and CELC carries about $321.9M in long‑term debt. At the same time, Celcuity Inc. holds a large cash and investments cushion, with current assets around $465.66M and a strong current ratio of 10.6. For traders, that combo screams “high‑risk, catalyst‑driven story with runway,” not a steady earnings play.

Why Traders Are Watching CELC Right Now

CELC is on radar screens because the clinical and regulatory story just hit a new gear. Celcuity Inc. announced that its Phase 3 VIKTORIA‑1 trial in PIK3CA‑mutant HR+/HER2‑ metastatic breast cancer met its primary endpoint. Gedatolisib plus fulvestrant, with or without palbociclib, delivered statistically significant and clinically meaningful improvements in progression‑free survival versus alpelisib plus fulvestrant. For traders, that’s the kind of clean, binary readout that can reprice a biotech overnight.

The key here is not only that VIKTORIA‑1 hit. It’s that CELC is pairing strong efficacy with a “generally well‑tolerated” and “manageable” safety profile. Many oncology names stumble on toxicity once you get to Phase 3. Celcuity Inc. is signaling that gedatolisib held up under the pressure in both triplet and doublet regimens.

At the same time, Citizens has stepped in with fresh coverage, slapping an Outperform rating and a $150 price target on CELC. That target, anchored to gedatolisib’s potential, assumes value from both the PIK3CA‑mutant and wild‑type populations. The bank flagged the VIKTORIA‑1 data and an expected first approval in July for PIK3CA wild‑type patients as core drivers.

Layer on the existing Priority Review for gedatolisib in the wild‑type setting, with a 2026/07/17 PDUFA date, and traders suddenly have a clear catalyst calendar. Celcuity Inc. now plans a supplemental NDA based on the mutant‑cohort results, aiming to build a broad second‑line HR+/HER2‑ breast cancer franchise. That kind of multi‑setting opportunity is exactly what fuels sustained trading interest in CELC, especially while the chart is already trending higher.

More Breaking News

Conclusion

CELC is acting like a textbook catalyst runner: strong news, heavy attention, and a chart that confirms the story. Celcuity Inc. has moved gedatolisib from “promising” to “late‑stage winner” territory in HR+/HER2‑ advanced breast cancer, with Phase 3 VIKTORIA‑1 data that beat alpelisib plus fulvestrant on progression‑free survival and showed manageable safety. With Priority Review already in place for PIK3CA wild‑type patients and a 2026/07/17 PDUFA date circled, Celcuity Inc. is lining up multiple shots on goal via an sNDA for the mutant population.

Financially, CELC is still burning cash and posting steep losses, but it holds significant liquidity and the balance sheet gives the company time to execute its regulatory plan. That’s why the market is willing to pay a rich multiple today: traders are discounting tomorrow’s potential franchise revenues, not today’s income statement.

For active traders, the message is simple: respect the trend but never forget the risk. CELC is a high‑volatility biotech tied to a handful of regulatory decisions and commercial outcomes. As Tim Sykes likes to remind his students, “The rules are simple: cut losses quickly, stick to your plan, and never believe the hype — verify it on the chart.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. CELC’s story is powerful, but trading it still demands discipline, a clear risk level, and a willingness to step aside if the price action cracks.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading CELC

Millionaire's
POV on CELC

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”